Cite
HARVARD Citation
Nagasaka, M. et al. (2022). Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung cancer. pp. 52-55. [Online].